Recruiting PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT06252454

The Impact of Inhaled Furosemide and Perorally Administered Levodropropizine on Dyspnea in Patients With Respiratory Diseases (INFURO)

Sponsor: Masaryk University

Conditions Dyspnea

Interventions Furosemide 40 mg Levodropropizine Placebo - saline

Updated 4 times since 2024 Last updated: Apr 15, 2024 Started: Feb 27, 2024 Primary completion: Dec 31, 2024 Completion: Dec 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Dyspnea, this trial is actively recruiting participants. The trial is conducted by Masaryk University and has accumulated 4 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
May 2024 — Jul 2024 [monthly]

Recruiting PHASE2_PHASE3

Status: Not Yet Recruiting → Recruiting
Mar 2024 — May 2024 [monthly]

Not Yet Recruiting PHASE2_PHASE3

First recorded

Feb 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Masaryk University
University Hospital Hradec Kralove

Data source: University Hospital Hradec Kralove

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hradec Králové, Czechia